SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Myeloproliferative neoplasm that is consistently associated with the BCR-ABL1 fusion gene located in the Philadelphia chromosome; originates in an abnormal bone marrowstem cell.
Diagnosis of this disease is usually incidental (85% are asymptomatic when diagnosed) when the patient has a CBC and/or peripheral blood smear. If the results of the WBC are abnormal (elevated) the physician will order a bone marrow aspiration.
CML has four phases: 1. Accelerated phase - can last weeks to months. 2. Chronic phase - involvement is usually limited to blood, bone marrow and spleen, although the liver may be infiltrated. 3. Blastic phase - lymph nodes and tissue may be involved. The blastic phase is a disease progression from the chronic phase. The disease; however, remains the same histology: Chronic myelogenousleukemia. 4. Terminal phase - last phase and survival is usually only weeks or months.
Treatment information: Chronic phase: Tyrosine kinase inhibitor; high-dose chemotherapy with donor cell transplant; BRM (interferon) with or without chemotherapy. May also have single or multi-agent chemotherapy and splenectomy.
Accelerated phase: Donor stem cell transplant; tyrosine kinase inhibitor; BRM (interferon) with or without chemotherapy.
Blast phase: Tyrosine kinase inhibitor; single or multi-drug chemotherapy; donor stem cell transplant.
Aspirin was previously documented as treatment for this disease. This was found to be incorrect. Treatment has been updated based on the NCI website (updated 6/12/15)